Search Results - "Prats, José Vicente Torregrosa"

Distar Renal Tubular Acidosis (dRTA): Epidemiological, diagnostics, clinical follow-up and therapeutical issues. Nephrologists cohort survey outcome by Torregrosa Prats, José Vicente, Santos Rodríguez, Fernando, González Parra, Emilio, Espinosa Román, Laura, Buades Fuster, Juan Manuel, Monteagud-Marrahí, Enrique, Navas Serrano, Victor Manuel

“…BACKGROUND AND OBJECTIVESdRTA is a genetic or acquired rare disease, characterized by an unability to excrete hydrogens (H+) into urine, hypobicarbonatemia,…”
Get full text

Distar Renal Tubular Acidosis (dRTA): Epidemiological, diagnostics, clinical follow-up and therapeutical issues. Nephrologists cohort survey outcome by Torregrosa Prats, José Vicente, Rodríguez, Fernando Santos, Parra, Emilio González, Román, Laura Espinosa, Buades Fuster, Juan Manuel, Monteagud-Marrahí, Enrique, Navas Serrano, Victor Manuel

“…dRTA is a genetic or acquired rare disease, characterized by an unability to excrete hydrogens (H+) into urine, hypobicarbonatemia, hyperchloremia, and…”
Get full text

Acidosis tubular renal distal (ATRd): aspectos epidemiológicos, diagnósticos, de seguimiento clínico y terapéuticos. Resultados de una encuesta a un colectivo de nefrólogos by Torregrosa Prats, José Vicente, Santos Rodríguez, Fernando, González Parra, Emilio, Espinosa Román, Laura, Buades Fuster, Juan Manuel, Monteagud-Marrahí, Enrique, Navas Serrano, Victor Manuel

“…La acidosis tubular renal distal (ATRd) es una enfermedad minoritaria, de origen genético o adquirido, caracterizada por una incapacidad de excreción urinaria…”
Get full text

2504 Histopathological findings and cardiovascular events in kidney transplantation by Espinosa, Diana Rodríguez, Hermida, Evelyn, Cúpich, Agustín Leal, Cuadrado, Elena, Escudero, Victor Joaquin, Morantes, Laura, García-Herrera, Adriana, Diekmann, Fritz, Monzo, Jose Jesus Broseta, Prats, José Vicente Torregrosa

“…Abstract Background and Aims Despite offering superior outcomes for patients with end-stage kidney disease, kidney transplantation poses significant…”
Get full text

A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism by Cruzado, Josep M, Moreno, Pablo, Torregrosa, José V, Taco, Omar, Mast, Richard, Gómez-Vaquero, Carmen, Polo, Carolina, Revuelta, Ignacio, Francos, José, Torras, Joan, García-Barrasa, Arantxa, Bestard, Oriol, Grinyó, Josep M

“…Tertiary hyperparathyroidism is a common cause of hypercalcemia after kidney transplant. We designed this 12-month, prospective, multicenter, open-label,…”
Get full text

2908 Renal progenitor cells an early non-invasive biomarker of silent kidney injury in Fabry disease by Ugalde-Altamirano, Jessica, Juarez, Jordi Rovira, Tubita, Valeria, Plana, Josep Maria Campistol, Poch, Esteban, Diekmann, Fritz, Piñeiro, Gaston, Cucchiari, David, Azorin, Sebastian, Banon, Elisenda, Corral-Velez, Vicente, Prats, José Vicente Torregrosa

“…Abstract Background and Aims Fabry's disease (FD), a hereditary condition, is linked to the X chromosome due to a mutation in the gene encoding…”
Get full text

3006 Therapeutic apheresis in Fabry disease by Ugalde-Altamirano, Jessica, Juarez, Jordi Rovira, Plana, Josep Maria Campistol, Lozano, Miquel, Cid, Joan, Piñeiro, Gaston, Ramirez, Maria Jose, Corral-Velez, Vicente, Revuelta, Ignacio, Roca, Ramon, Calls, Jordi, Prats, José Vicente Torregrosa

“…Abstract Background and Aims Fabry's disease (FD) is a rare lysosomal disorder linked to the X chromosome due to a mutation in the gene encoding…”
Get full text

C.E.R.A administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II by Martínez Castelao, Alberto, Cases Amenós, A. (Aleix), Coll Piera, Elisabeth, Bonal, Jordi, Galcerán, Josep M, Fort, Joan, Moreso, Francesc, Torregrosa Prats, José Vicente, Guirado, Lluís, Ruiz, Pilar, Investigators of the Micena II Study

“…BACKGROUND AND OBJECTIVE: C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in…”
Get full text

Kidney transplant from a living monozygotic twin donor with no maintenance immunosuppression by Sánchez-Escuredo, Ana, Barajas, Alberto, Revuelta, Ignacio, Blasco, Miquel, Cofan, Federic, Esforzado, Núria, Ricart, María José, Torregrosa, Vicens, Campistol, Josep Maria, Oppenheimer, Federic, Diekmann, Fritz

“…From a theoretical point of view, an alloimmune response can not take place, still some type of standard immunosuppression is used in about 60% of patients…”
Get full text

Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure by Marrades, R M, Roca, J, Campistol, J M, Diaz, O, Barberá, J A, Torregrosa, J V, Masclans, J R, Cobos, A, Rodríguez-Roisin, R, Wagner, P D

“…Erythropoietin (rHuEPO) has proven to be effective in the treatment of anemia of chronic renal failure (CRF). Despite improving the quality of life, peak…”
Get full text

Cellular bioenergetics after erythropoietin therapy in chronic renal failure by Marrades, R M, Alonso, J, Roca, J, González de Suso, J M, Campistol, J M, Barberá, J A, Diaz, O, Torregrosa, J V, Masclans, J R, Rodríguez-Roisin, R, Wagner, P D

“…After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O2 uptake (VO2 peak) as much as expected from the rise in…”
Get full text